Allarity Therapeutics, Inc. has announced the termination of its equity line of credit agreement with Tumim Stone Capital LLC, effectively halting a planned offering of up to $6 million in common stock. This decision, filed with the SEC on October 30, 2026, marks a significant shift in the company’s funding strategy.

The termination of the Purchase Agreement is effective as of October 28, 2026. The company stated that it will not offer or sell any additional shares under the agreement, and the previous prospectus supplement may no longer be utilized for further sales.

Background

Allarity Therapeutics, Inc. is a company focused on pharmaceutical preparations, operating under the ticker symbol ALLR on the Nasdaq exchange. The company is categorized as an emerging growth entity, and its recent filings include a mix of 8-K and 424B5 forms, reflecting ongoing corporate activities and financial disclosures.

What the Filing Says

The SEC filing indicates, "We terminated the Purchase Agreement effective October 28, 2026. Accordingly, the primary offering of additional shares of our common stock under the Original Prospectus Supplement is hereby terminated." This statement clarifies the cessation of the stock offering and the implications for future financing.

Impact

This decision may affect various stakeholders, including current investors and potential shareholders, as it alters the company's approach to capital raising. The pharmaceutical preparations industry, represented by Allarity, may also see shifts in how companies pursue funding, especially in the face of evolving market conditions.

What's Next

The filing does not say what happens next.